Skip to content
Menu

RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $6

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target from $40 to $6.

RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target from $40 to $6.

Read at benzinga.com